Menu Search
Equities

Intellego Technologies AB

7RW:FRA

Intellego Technologies AB

Actions
  • Price (EUR)3.18
  • Today's Change-0.035 / -1.09%
  • Shares traded1.18k
  • 1 Year change+154.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intellego Technologies AB is a Sweden-based company engaged in photochromatic indicator technology. The Company is a manufacturer of colorimetric ultraviolet indicators. UVC Dosimeters are used in Healthcare, Hospitality, Retail, Transportation and Commercial Applications around the world. With its patented photochromic ink that changes color based on exposure to ultraviolet irradiation or specific substances, Intellego produces dosimeters in a variety of formats and custom options to meet the constantly evolving needs of Ultraviolet Device Manufacturers (OEMs) and end-users. Intellego Technologies is headquartered in Stockholm, with product development and manufacturing based in the southwest region of Sweden.

  • Revenue in SEK (TTM)231.25m
  • Net income in SEK82.86m
  • Incorporated2011
  • Employees62.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.